



SUGGESTED FORMULA

Retinoic Acid 0.05% Topical Cream

Version number: 1.0

Volume or quantity: 100 gm

Retinoic Acid (Tretinoin, Powder, USP)* (R1022)	0.05 gm
Butylated Hydroxytoluene, NF (B1196)	0.4gm
Polysorbate 80, NF (PO138)	3mL
Propylene Glycol, USP (PR130)	2.5mL
Sodium Metabisulfite, NF (SO182)	0.3gm
Alcohol 190 Proof, USP (ET108)	XmL
Vanishing Cream Base (B1285)	QS 100gm

SUGGESTED COMPOUNDING PROCEDURES

Weigh all ingredients

- 1. Measure all ingredients
- 2. Transfer Butylated Hydroxytoluene to mortar and triturate crystals to fine powder
- 3. Add enough Propylene Glycol to form paste, then add remaining Propylene Glycol
- 4. Add Polysorbate 80 and mix well
- 5. Using geometric dilution add Vanishing Cream Base and mix well
- 6. Process step 6 through ointment mill and/or electronic mortar and pestle to reduce grit
- 7. Dissolve Retinoic Acid in a small amount of Alcohol and mix into cream by geometric dilution until homogeneous
- 8. Package and label
- 9. Suggested Quality assessments:
 - a. colorb. texturec. container
 - d. Label auxiliary labels, storage, BUD, compounded medication

Store in light resistant air-tight container, at Controlled room temperature

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates from reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date. It is recommended that you follow USP <795> recommendations for potency testing.

Beyond-Use Date estimated to be 30 days Per quidelines of USP Chapter <795>

*Precautions:

Hazardous drugs should be handled according to USP and NIOSH standards and pharmacy SOPs. This preparation should be compounded in a vertical airflow hood, in a biological safety cabinet or barrier isolation technology. Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate personal protective equipment.

9/18 JD